Side-by-side · Research reference

CrystagenvsPNC-27

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-MechanisticHUMAN-REVIEWED12/40 cited

BAnimal-StrongHUMAN-REVIEWED18/41 cited

Crystagen

Khavinson Bioregulator · Immune-Thymic

B-cellPrimary targetСhervyakova 2014

SpleenTissue specificityСhervyakova 2014

AnimalEvidence level

SQ · Protocol variable

PNC-27

p53-HDM-2 Peptide · Membrane-Targeting

32 AAPeptide lengthSarafraz-Yazdi 2022

12-26p53 domain

Pre-clinicalDevelopment stage

In vitro / Pre-clinical only

01Mechanism of Action

Parameter

Crystagen

PNC-27

Primary target

B-lymphocytes in splenic tissueСhervyakova 2014

Membrane-bound HDM-2 protein on cancer cell surfaceSarafraz-Yazdi 2022 Krzesaj 2024

Pathway

B-cell activation → Immune modulation during agingСhervyakova 2014

PNC-27 binds to membrane HDM-2 1-109 domain → transmembrane pore formation → rapid necrosis (poptosis)Pincus 2024 Krzesaj 2024

Downstream effect

B-cell activation via apoptosis reduction; no observed increase in splenic cell renewalСhervyakova 2014

Immediate cell lysis and extrusion of intracellular contents; secondary mitochondrial membrane disruptionPincus 2024 Krzesaj 2024

Feedback intact?

Unknown — bioregulator mechanism not fully characterized

N/A — cytotoxic mechanism, not signaling modulation

Origin

Synthetic Lys-Glu-Asp-Gly tetrapeptide — Khavinson bioregulator series

Chimeric design: p53 transactivating domain (12-26) fused to penetratin CPP sequenceSarafraz-Yazdi 2022

Antibody development

—

02Dosage Protocols

Parameter

Crystagen

PNC-27

Standard dose

Not standardized — variable protocols

Russian bioregulator literature does not specify unified human dosing.

—

Evidence basis

Animal / mechanistic

Pre-clinical / In vitro

Route

Subcutaneous (presumed from bioregulator class)

—

Frequency

Unknown — bioregulator protocols variable

—

Duration

Unknown — chronic administration presumed in animal models

—

Half-life

Not reported

—

Clinical status

—

Pre-clinical only — no human trials

In vitro and animal model data only.

In vitro concentrations

—

10–100 μM range

Effective concentrations in cell culture studies.

Shorter analogue

—

PNC-28 (28 AA variant)

Retains HDM-2 binding and cytotoxic activity.

03Metabolic / Fat Loss Evidence

Parameter

Crystagen

PNC-27

Fat loss mechanism

—

None — cytotoxic anticancer agent

04Side Effects & Safety

Parameter

Crystagen

PNC-27

Published adverse events

None reported in available animal literature

—

Human safety data

Absent — no controlled human trials identified

None available — no human trials conducted

Autoimmune considerations

Theoretical concern with B-cell modulators in predisposed individuals

—

Normal cell selectivity

—

In vitro: no cytotoxicity to normal cells (MCF-10-2A, peripheral blood mononuclear cells)Sarafraz-Yazdi 2010 Thadi 2020

Normal cells express minimal membrane HDM-2.

Cancer cell specificity

—

Depends on membrane HDM-2 expression levels

Ovarian cancer lines with low membrane HDM-2 showed <30% necrosis.

Cell death mechanism

—

Necrosis (not apoptosis) — rapid membrane lysisPincus 2024

Mitochondrial effects

—

Secondary mitochondrial membrane disruption in cancer cells

Absolute Contraindications

Crystagen

·Active autoimmune disease (theoretical)

PNC-27

·Human use — no clinical trials or safety data

Relative Contraindications

Crystagen

·Pregnancy / lactation (no data)
·Active B-cell malignancies

PNC-27

—

05Administration Protocol

Parameter

Crystagen

PNC-27

1. Route

Subcutaneous injection — presumed from bioregulator class convention. Specific anatomical sites not standardized.

PNC-27 has not been tested in human subjects. All data derive from in vitro cancer cell line studies and limited animal models. No approved clinical formulation, dosing protocol, or safety profile exists.Pincus 2024

2. Reconstitution

Protocol not standardized. If lyophilized, sterile water or bacteriostatic saline typical for peptide bioregulators.

In vitro studies used 10–100 μM PNC-27 dissolved in cell culture medium. Peptide was added directly to cancer cell cultures (pancreatic, breast, colon, ovarian, leukemia lines) and incubated for 24–72 hours.

3. Timing

Not specified. Bioregulator protocols vary — some practitioners advocate evening dosing, others morning.

Dual-labeled PNC-27 (green on N-terminus, red on C-terminus) demonstrated intact peptide binding to cancer cell membranes with combined yellow fluorescence at 30 minutes, persisting during cell lysis.Sookraj 2010

4. Storage

Lyophilized: room temperature, light-protected. Reconstituted: refrigerate, use within days to weeks depending on preservative.

Cytotoxicity correlates directly with membrane HDM-2 expression levels. Blocking HDM-2's p53-binding domain (1-109) with monoclonal antibodies prevents PNC-27-induced necrosis.

06Stack Synergy

Crystagen

+ Vilon

Multi-pathway

View Vilon →

Vilon (Lys-Glu) activates T-helper cells via apoptosis reduction, while Crystagen activates B-cells. Dual T/B immune modulation in aging models may provide complementary thymic-immune support within the Khavinson bioregulator framework. Both target splenic immune aging through distinct lymphocyte subsets.

Crystagen: Dose unknown · SQ
Vilon: Dose unknown · SQ
Frequency: Protocol variable
Primary benefit: Broader thymic-immune coverage (T-cell + B-cell)

Сhervyakova 2014

PNC-27

— no documented stacks